Journals / Türk Geriatri Dergisi / 2012 / Cilt: 15 - Sayı: 2

En yaşlı gruplarda primer ve sekondor koruma için statinler: Var olan kanıtların değerlendirilmesi

Statins for primary and secondary prevention in the oldest old: An overview of the existing evidence

Pages
223–228
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, the systematic use of statins in older patients with hypercholesterolemia needs to be further investigated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hypercholesterolemia, although a modifiable risk factor for cardiovascular disease, is still one of the leading causes of death among older people in western countries.
📊
Key Findings & Data:The use of statins among cholesterol reducing agents in both primary and secondary prevention has not been extensively studied in older patients in contrast to middle-aged patients.
💡
Conclusion & Impact:Therefore, the systematic use of statins in older patients with hypercholesterolemia needs to be further investigated.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hypercholesterolemia, although a modifiable risk factor for cardiovascular disease, is still one of the leading causes of death among older people in western countries. The use of statins among cholesterol reducing agents in both primary and secondary prevention has not been extensively studied in older patients in contrast to middle-aged patients. Despite a growing body of evidence in secondary prevention, statins are still under utilized in older patients with established vascular disease. On the other hand, the benefits of statins in primary prevention are not so clear. Therefore, the systematic use of statins in older patients with hypercholesterolemia needs to be further investigated.

Özet

Hiperkolesterolemi, kardiyovasküler hastalık için değiştirilebilir bir risk faktörü olmasına rağmen, halen batı ülkelerinde yaşayan yaşlılar arasında önde gelen ölüm nedenlerinden biridir. Primer ve sekonder önlenmesinde ilaçlar kolesterol düşürücü statin arasında kullanımı yaygın, orta yaşlı hastalarda aksine yaşlı hastalarda çalışılmamıştır. Kurulan vasküler hastalığı olan yaşlı hastalarda kullanılan altında ikincil önleme kanıtların artmasına rağmen, statinler hala. Diğer taraftan, primer önlenmesinde statinler yararlarını çok açık değildir. Bu nedenle, hiperkolesterolemi ile yaşlı hastalarda statinlerin sistematik kullanımı daha da araştırılması gerekir.

🔖

Cite This Article

WERBROUCK, B., NOORTGATE, N. V. D., PETROVIC, M. (2022). En yaşlı gruplarda primer ve sekondor koruma için statinler: Var olan kanıtların değerlendirilmesi. Türk Geriatri Dergisi, Cilt: 15 - Sayı: 2, 223–228. https://ajindex.com/articles/623995

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Walker D, Jacobson T. Initiating statins in the elderly: the evolving challenge. Curr Opin Endocrinol Diabetes Obes 2008;15(2):182-7. (PMID:183l6955)
  2. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001;5(4):378-87. (PMID: 12067471)
  3. Lewington S, Whitlock G, Clarke R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a metaanalysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39. (PMID: 1806105 8)
  4. Conroy RM, Pyörâlâ K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24(11):987-1003. (PMID: 12788299)
  5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18): 1837-47. (PMID:9603539)
  6. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152(8):488-96. (PMID:20404379)
  7. Casiglia E, Spolaore P, Ginocchio G, et al. Predictors of mortality in very old subjects aged 80 years or over. Eur J Epidemiol 1993;9(6):577-586. (PMID:8150059)
  8. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350(9085): 1119-23 (PMID:9343498)
  9. Schatz IJ, Masaki K, Yano K, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358(9279):351-5. (PMID: 11502313)
  10. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R. Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005;53(2):219-26. (PMID:15673344)
  11. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing 2010;39(6):674-80. (PMID:20952373)
  12. Heart Protection Study Collaborative. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011;378(9808):2013-20. (PMID-.22115874)
  13. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in eld- berly individuals at ris